To understand the role of SPA17 in predicting the efficacy of immune checkpoint inhibitor (ICI) therapy, we assessed the correlation between the expression of SPA17 and two well-known immunotherapy predictive biomarkers (34, 35), tumor mutation burden (TMB) and microsatellite instability (MIS). The gene discussed is SPA17; the disease is neoplasm.